Dr. Yajing Chen joined Zai Lab in September 2021 and currently serves as Chief Financial Officer.
Dr. Chen is a seasoned finance executive and leader with more than 20 years of experience in the life sciences industry as well as a Ph.D. trained scientist. Dr. Chen’s scientific background combined with her significant executive management experience, finance expertise at leading global companies, and business acumen allow her to bring a unique perspective to Zai Lab.
Dr. Chen was promoted to the position of Chief Financial Officer in July 2023. She previously served as the Company’s Senior Vice President and Deputy Chief Financial Officer since September 2021. Dr. Chen joined the Company from AstraZeneca where she held various roles of increasing responsibility from 2006 to 2021, including Chief Financial Officer for the U.S. Oncology Business Unit from 2019 to 2021 and Finance Controller of the Global Oncology Business Unit from 2016 to 2019. In these roles, Dr. Chen led financial planning and analysis as well as the development of a long-term strategic plan for the oncology therapy area, guiding business development, pipeline prioritization, and commercial strategy and enabling substantial revenue growth for their global oncology business.
Dr. Chen earned a Ph.D. in Microbiology from New York University and an MBA from Columbia University.
